CytomX Therapeutics (STU:6C1) Other Net Income (Loss) : €0.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is CytomX Therapeutics Other Net Income (Loss)?

CytomX Therapeutics's Other Net Income (Loss) for the three months ended in Dec. 2024 was €0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.0 Mil.

CytomX Therapeutics's quarterly Other Net Income (Loss) increased from Jun. 2024 (€-0.0 Mil) to Sep. 2024 (€0.0 Mil) and increased from Sep. 2024 (€0.0 Mil) to Dec. 2024 (€0.0 Mil).

CytomX Therapeutics's annual Other Net Income (Loss) declined from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€-0.0 Mil) and declined from Dec. 2023 (€-0.0 Mil) to Dec. 2024 (€-0.0 Mil).

CytomX Therapeutics Other Net Income (Loss) Historical Data

The historical data trend for CytomX Therapeutics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytomX Therapeutics Other Net Income (Loss) Chart

CytomX Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Net Income (Loss)

Get a 7-Day Free Trial

CytomX Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

CytomX Therapeutics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

CytomX Therapeutics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

CytomX Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

CTMX:USA 6C1:Germany

Address

151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.cytomx.com

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Headlines

No Headlines